Q-omics provides the consensus-scored ARSJ profile across patient tissues and cancer cell-line models. ARSJ expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARSJ is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ARSJ RNA expression shows 18,748 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, HNSC, and KIRP as cancer lineages where ARSJ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARSJ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARSJ survival associations across molecular data types. ARSJ RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARSJ RNA expression–survival associations across cancer types. High ARSJ expression shows unfavorable associations in UVM, ACC, BLCA and LGG, but favorable associations in SKCM and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARSJ RNA expression.
This table summarizes ARSJ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ARSJ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARSJ shows lower tumor expression in BLCA and BRCA and higher tumor expression in HNSC, THCA, KICH and CHOL. The HNSC box plot shows higher ARSJ RNA expression in tumor versus normal tissue (log2 FC = +2.451, t-test p < 0.001).
This table shows molecular features associated with ARSJ in patient tissues and cancer cell lines. In patient samples, ARSJ shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ARSJ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
